NATERA ALERT: Bragar Eagel & Squire, P.C. is Investigating Natera, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmBusiness Wire • 12/27/23
Natera Announces New Study Highlighting the Benefits of Signatera's Unique Method of Quantifying ctDNABusiness Wire • 12/21/23
Delaware Court Denies CareDx's Motion for Summary Judgment on Two Natera PatentsBusiness Wire • 12/11/23
Natera Presents New Signatera™ MRD Data Across Breast Cancer Treatment Settings at SABCS 2023Business Wire • 12/06/23
Natera Announces Randomized, Phase III TREAT ctDNA Trial in Early-Stage Breast CancerBusiness Wire • 11/08/23
Natera's Landmark RenaCARE Study Demonstrates Significant Diagnostic and Clinical Utility of Renasight™ in Chronic Kidney DiseaseBusiness Wire • 11/02/23
Updated Data from CIRCULATE-Japan Presented at ESMO 2023 Reinforces Signatera's Prognostic and Predictive Value in Analysis of 2,500+ Colorectal Cancer PatientsBusiness Wire • 10/22/23
Natera to Present New Signatera™ MRD Data at ESMO 2023, Featuring Large, Updated Analysis from CIRCULATE-Japan StudyBusiness Wire • 10/16/23
New MRD Publication in Unresectable Stage I-III Lung Cancer Demonstrates Signatera's Ability to Risk Stratify and Detect Progression EarlyBusiness Wire • 10/04/23
Natera Announces Expanded I-SPY 2 Collaboration to Evaluate Signatera™ for Breast Cancer Patients in the Neoadjuvant SettingBusiness Wire • 09/14/23
CareDx Announces District Court Judge Bars Natera from Falsely Advertising and Overstating the Scientific Performance of its Prospera Transplant TestBusiness Wire • 08/07/23